Found 2137 clinical trials
Study to Assess the Efficacy Safety and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)
Primary Objective: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former …
- 633 views
- 22 Sep, 2022
- 56 locations
Multiple Sclerosis
LIVING WITH MULTIPLE SCLEROSIS?The purpose of this study is to find out the effect of the study drug, on the body in patients with MS by assessing your
- 0 views
- 28 Oct, 2021
- 1 location
A research study for patients who have been diagnosed with multiple sclerosis
A research study for patients who have been diagnosed with multiple sclerosis
- 399 views
- 23 Nov, 2020
- 1 location
A research study for patients who have been diagnosed with multiple sclerosis
A research study for patients who have been diagnosed with multiple sclerosis
- 820 views
- 23 Nov, 2020
- 1 location
Apathy and Reward Systems in Alzheimer’s Disease
This study is looking for people over the age of 65 who have either early stage Alzheimer’s/mild cognitive impairment or depression. The study is interested in examining cognition and brain characteristics, and their relationship with Alzheimer’s and depression.
- 34 views
- 24 May, 2022
- 1 location
Multiple Sclerosis - (MS) Primary Progressive Multiple Sclerosis
Multiple Sclerosis - (MS) Primary Progressive Multiple Sclerosis
- 402 views
- 08 Nov, 2020
- 1 location
A study of rHIgM22 dosage in relapsing MS patients.
A study of rHIgM22 dosage in relapsing MS patients.
- 200 views
- 23 Nov, 2020
- 1 location
An Open Label, 26-Week Study Assessing Arbaclofen Placarbil Safety and Efficacy in Subjects With Spasticity Associated With Multiple Sclerosis With an Addendum Open-Label, 36-Week Study Assessing Arbaclofen Placarbil Safety in Subjects With Spasticity Associated With Multiple Sclerosis
An Open Label, 26-Week Study Assessing Arbaclofen Placarbil Safety and Efficacy in Subjects With Spasticity Associated With Multiple Sclerosis With an Addendum Open-Label, 36-Week Study Assessing
- 207 views
- 08 Nov, 2020
- 1 location
Living with Multiple Sclerosis? Enrolling for a 96-week, non-placebo, comparative trial.
Living with Multiple Sclerosis? Enrolling for a 96-week, non-placebo, comparative trial.
- 428 views
- 08 Nov, 2020
- 1 location
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
- 204 views
- 08 Nov, 2020
- 1 location